PERNIX THERAPEUTICS HLDGS IN - DBCV 4.250% 4/0

CUSIP: 71426VAK4

Q2 2018 13F Holders as of 30 Jun 2018

Type / Class
Debt / DBCV 4.250% 4/0
Market price (% of par)
43.13%
Total 13F principal
$69,725,000
Principal change
$0
Total reported market value
$28,834,000
Number of holders
12

Quarterly Holders Quick Answers

What is CUSIP 71426VAK4?
CUSIP 71426VAK4 identifies 71426VAK4 - PERNIX THERAPEUTICS HLDGS IN - DBCV 4.250% 4/0 in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of PERNIX THERAPEUTICS HLDGS IN - DBCV 4.250% 4/0 as of Q2 2018

As of 30 Jun 2018, PERNIX THERAPEUTICS HLDGS IN - DBCV 4.250% 4/0 was held by 12 institutional bondholders reporting positions in Form 13F filings. These institutions reported holding $69,725,000 in principal (par value) of the bond. The largest 10 bondholders included ARMISTICE CAPITAL, LLC, Broadfin Capital, LLC, Telemetry Investments, L.L.C., venBio Select Advisor LLC, Jefferies Group LLC, Aisling Capital LLC, ZAZOVE ASSOCIATES LLC, TENOR CAPITAL MANAGEMENT Co., L.P., Bruce & Co., Inc., and CITADEL ADVISORS LLC. This page lists 12 institutional bondholders reporting positions for the Q2 2018 filing period.
Investor Option Weight % Change % Value $ * Price (% of par) Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.